Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07748468

Impact of Antioxidant-rich Supplementation on Skin Carotenoids Status, Antioxidant Status and Cardiometabolic Health in Overweight and Obese Individuals

This study aims to evaluate the effects of antioxidant-rich supplementation on skin carotenoid status, antioxidant status, and cardiometabolic health in overweight and obese individuals. The study may provide additional scientific evidence to support the further refinement of current dietary and nutritional recommendations.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Overweight , Obesity Antioxidant Status Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

21 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07, Singapore, 117550

Singapore, 117542

Location contact

Jung Eun Kim, Ph.D., R.D.

PRINCIPAL_INVESTIGATOR

Lingyin Yu, B.Sc.

CONTACT

[email protected]

(+65) 8942 1809

About this study

This study will be a single-blind, randomized, parallel-group trial, and all participants will complete a 12-week study period. A total of 66 participants will be recruited and randomly assigned to continue their habitual diet with or without antioxidant-rich supplementation. This study aims to investigate whether antioxidant-rich supplementation will influence body composition, skin carotenoid status, antioxidant status, and cardiometabolic health. The study will comprise 1 screening visit and 4 test visits.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to give informed consent (AMT score ≥ 8 for older adults [65-70 years old])
  • Adults 21-70 years old
  • English-literate
  • Have venous access sufficient to allow for blood sampling as per the protocol
  • No drastic change of diet for the past 1 year
  • If taking medication, has been consistently taking antihypertensive/cholesterol-lowering/type-2 diabetic medication for more than 3 years prior to starting the study

Exclusion criteria

  • Weight change > 3kg in the past 3 months
  • Exercising vigorously over the past 3 months
  • Taking medications or dietary supplements which may impact eye/skin health
  • Taking lipid-lowering and blood pressure controlling medications less than 3 years
  • Smoking
  • Drinking more than 2 alcoholic drinks per day
  • Pregnant, lactating, or planning pregnancy in the next 6 months

Treatment and study plan

Antioxidant-rich supplementation Element

Dietary Supplement

Maintained habitual diet with additionally taking LifePak Element for 12 weeks

Antioxidant-rich supplementation Optimal

Dietary Supplement

Maintaining habitual diet with additionally taking LifePak Optimal for 12 weeks

Primary outcomes

  1. Change in Skin Carotenoid Score Measured by Prysm iO™ from Baseline to Week 12

    Time frame: Week 0, 4, 8, 12

    Skin carotenoid status will be assessed using the Prysm iO™ device. The device scans the participant's fingertip and provides a skin carotenoid score, also referred to as the Prysm Score. Results will be reported as the numerical Prysm Score. Higher scores indicate higher skin carotenoid levels.

  2. Mean Change from Baseline in Blood Carotenoid Concentration

    Time frame: Week 0 and Week 12

    Blood carotenoid concentration will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in blood carotenoid concentration at Week 12. Higher concentrations indicate higher circulating carotenoid status.

Secondary outcomes

  1. Mean Change from Baseline in Total Antioxidant Capacity in Blood Samples

    Time frame: Week 0 and Week 12

    Total antioxidant capacity will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in total antioxidant capacity at each post-baseline time point.

  2. Mean Change from Baseline in Fasting Blood Lipid and Lipoprotein Concentrations

    Time frame: Week 0 and Week 12

    Fasting blood lipid and lipoprotein concentrations will be assessed using blood samples collected from participants after an overnight fast. The lipid and lipoprotein profile may include total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Results will be reported as the mean change from baseline in each lipid and lipoprotein parameter at Week 12.

  3. Mean Change from Baseline in Fasting Blood Glucose Concentration

    Time frame: Week 0 and Week 12

    Fasting blood glucose concentration will be assessed using blood samples collected from participants after an overnight fast. Results will be reported as the mean change from baseline in fasting blood glucose concentration at Week 12.

  4. Mean Change from Baseline in Fasting Blood Insulin Concentration

    Time frame: Week 0 and Week 12

    Fasting blood insulin concentration will be assessed using blood samples collected from participants after an overnight fast. Results will be reported as the mean change from baseline in fasting blood insulin concentration at Week 12.

  5. Mean Change from Baseline in Blood Biomarkers of Oxidative Stress: Malondialdehyde and 8-Isoprostane

    Time frame: Week 0 and Week 12

    Oxidative stress will be assessed using blood samples collected from participants. Blood biomarkers of oxidative stress will include malondialdehyde and 8-isoprostane. Results will be reported as the mean change from baseline in malondialdehyde concentration and 8-isoprostane concentration at Week 12. Higher concentrations indicate higher levels of oxidative stress.

  6. Mean Change from Baseline in Skin Autofluorescence Measured by AGE Reader mu Connect

    Time frame: Week 0, 4, 8, 12

    Skin advanced glycation end product accumulation will be assessed non-invasively using the AGE Reader mu Connect. The device measures skin tissue autofluorescence on the inside of the participant's dominant lower forearm. Results will be reported as the mean change from baseline in AGE Reader measurement result, expressed in arbitrary units. Higher values indicate higher skin advanced glycation end product accumulation.

  7. Mean Change from Baseline in Blood Advanced Glycation End Product Level

    Time frame: Week 0 and Week 12

    Blood advanced glycation end product level will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in blood advanced glycation end product level at Week 12.

  8. Mean change from baseline in anthropometric and body composition parameters

    Time frame: Week 0, 4, 8, 12

    Anthropometric and body composition parameters will be assessed using standard measurements and InBody body composition analysis. Parameters may include body weight, waist circumference, body fat percentage, fat mass, fat-free mass, skeletal muscle mass and body mass index. Results will be reported as the mean change from baseline at each post-baseline time point.

Other outcomes

  1. Mean Change from Baseline in Blood Clock Gene-Related Markers

    Time frame: Week 0 and Week 12

    Clock gene-related markers will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in selected clock gene-related markers at Week 12. This outcome is exploratory and will be used to explore potential biological changes associated with the intervention.

Study contacts

Contact information is provided by the study sponsor or research team.

Lingyin Yu, B.Sc.

CONTACT

[email protected]

(+65) 8942 1809

Sponsors and collaborators

Lead sponsor

National University of Singapore

Other

Collaborators

  • Nu Skin Enterprises

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 5, 2026
Registry last updated
Aug 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.